Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Why Farber Disease May Be Misdiagnosed as Juvenile Idiopathic Arthritis

Boris Hugle, MD, MSc, Laura Mueller & Thierry Levade, MD, PhD  |  Issue: June 2014  |  June 1, 2014

Farber disease is a rare, autosomal-recessive disorder caused by a mutation in the acid ceramidase gene, which leads to accumulation of sphingolipids in various tissues.1 It typically presents with a combination of characteristic subcutaneous nodules, progressive joint stiffness with contractures and progressive hoarseness starting in infancy.2 Additional symptoms include organ involvement, including the lungs, liver, heart and lymph nodes. Due to differences in residual lysosomal ceramidase turnover, great variability of phenotypes exists among patients with Farber disease. Patients with severe cases of Farber disease may exhibit various degrees of progressive, neurological dysfunction or liver failure, which, in many cases, leads to early death. Those with milder cases, without neurological or liver involvement, can survive well into adulthood.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

We report the case of a patient with late presentation of Farber disease without neurological involvement who was initially diagnosed with juvenile idiopathic arthritis.

Case report

A 2½-year-old boy of non-consanguineous German parents presented with hoarseness starting at age 18 months and an inability to extend the third finger of the right hand, noted at age 30 months. A biopsy of the finger yielded a result of chronic synovitis. Birth history and development to that point had been normal.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

On examination, he presented with significant limitation of motion of fingers II through V of both hands with thickening of the flexor tendon sheaths. He also had swelling of the ankles, knees, wrists and elbows, with significant pain and limitation of motion. Ultrasound at the time of presentation showed only mild effusions in the elbows, with no synovial thickening, but tenosynovitis of the flexor tendon sheaths. No subcutaneous nodules were noted.

A patient with late presentation of Farber disease at age 8 years and 1 month. Lateral view (A) and anterior view (B). Note the significant contractures of both knees and elbows, as well as swelling over wrists and ankles.

Figure 1: A patient with late presentation of Farber disease at age 8 years and 1 month. Lateral view (A) and anterior view (B). Note the significant contractures of both knees and elbows, as well as swelling over wrists and ankles.

Laboratory investigations showed normal CBC, negative CRP and ESR, and normal values for renal and liver function tests. Serum immunoglobulin levels for IgG, IgA and IgM were within normal range. Rheumatoid factor and antinuclear antibodies were not present, and HLA-B27 was negative.

He was tentatively diagnosed with juvenile idiopathic arthritis (with a subtype according to ILAR criteria of rheumatoid factor-negative polyarthritis) and was treated with indomethacin (2.7 mg/kg/day, divided three times per day), subcutaneous methotrexate (12.5 mg/m2 BSA/week) and several courses of methylprednisolone, which led to only temporary improvement.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:Juvenile idiopathic arthritisMethotrexatepatient careRheumatoid arthritisrheumatologist

Related Articles
    Kateryna Kon / Shutterstock.com

    How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease

    December 17, 2017

    Anemia is common in patients with systemic rheumatic disease, yet it may not get the attention it deserves. Anemia can result from chronic inflammation, treatment side effects or other disease factors, or it may signal an unrelated condition. Although diagnosis and treatment of anemia are sometimes challenging, clinicians must do their utmost to rigorously investigate…

    Diagnosis: Myopathy

    July 1, 2009

    Presentation and evaluation of metabolic causes

    New Methodology to Improve Cartilage Repair

    July 31, 2013

    A single treatment with recombinant acid ceramidase improves the chondrogenic phenotype of primary chondrocytes and leads to an increased yield of mesenchymal stem cells.  (posted July 31, 2013)

    The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy

    July 14, 2015

    CHICAGO—Scleroderma patients with pulmonary arterial hypertension (PAH) might benefit from more aggressive therapy, an expert in the field said in a session on lung involvement in rheumatic diseases at the American College of Rheumatology’s 2015 State-of-the-Art Clinical Symposium in May. Newer trials—the SERAPHIN trial on macitentan, GRIPHON on selexipag, and AMBITION on an ambrisentan/tadalafil combination—show…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences